ATS 2024 Final Program

Click on the session title to view the speakers

156

MONDAY • MAY 20

P584 A 3-year Descriptive Assessment of Exacerbations and Double/Triple Inhaler Use Among Chronic Obstructive Pulmonary Disease (COPD) Patients in the United States (US) P585 Characterization of Chronic Obstructive Pulmonary Disease (COPD) in the United States P586 Diagnostic Discordance of Chronic Obstructive Pulmonary Disease (COPD) in Veterans at the West Palm Beach Veterans Affairs Medical Center P587 The Impact of Hospital Academic Status on Morbidity and Mortality for Patients With Chronic Obstructive Pulmonary Disease in the United States: Insights From a Two-year Analysis of the National Inpatient Sample Development of Respiratory Tract Cancers in COPD: A Nationwide Population-based Study P589 Twenty-year Trends in Excess Costs of Chronic Obstructive Pulmonary Disease P588 The Effect of Inhaler Medications on the

P617 Determining Eligibility for Bronchoscopic Lung Volume Reduction: Results From the Cleveland Clinic Multidisciplinary Evaluation Team P618 A Review of Institutional Auto-Substitution Policy in the Management Chronic Obstructive Pulmonary Disease Patients P619 Adherence to the Guideline Recommendations in Chronic Obstructive Pulmonary Disease (COPD) Management of South Korea P620 Impact of Biologics in Patients With COPD and ACOS: A Real-world, Single-center Review of Factors Associated With Greater Reduction in Exacerbation Frequency P621 Dupilumab Increases the Proportion of Patients With Fractional Exhaled Nitric Oxide Levels Ë ppb Over Time in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: From Phase 3 Boreas Budesonide/Glycopyrrolate/Formoterol Fumarate in Chinese Patients With Chronic Obstructive Pulmonary Disease P623 Is Tiotropium Maintenance Therapy Necessary for All Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease? The Proportion, Clinical Characteristics, and Impact Factors of Patients With a Nonrapid Decline in FEV1 P624 Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Reduced Moderate/Severe Exacerbation Rate and Risk in Subjects With COPD Regardless of Baseline Blood Eosinophils P625 Ensifentrine Added on to LABA/ICS Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to-Severe COPD P626 Reduced Risk of Mortality for COPD Patients Associated with Initiation of Treatment with Single Inhaler Triple Therapy (Budesonide/Glycopyrrolate/Formoterol) Versus Multiple Inhaler Triple Therapy in the United States: The MAZI Study P627 Ivacaftor for Chronic Obstructive Pulmonary Disease- Results From a Phase 2, Randomized Controlled Trial P622 Effectiveness of

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B52 EVIDENCE FOR THERAPEUTIC STRATEGIES IN COPD: FROM ESTABLISHED TO EMERGING 9:15 a.m. - 4:15 p.m.

San Diego Convention Center Area F (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P614 An International Survey of Noninvasive Ventilation (NIV) Use for Acute Respiratory Failure: A Follow Up Survey P615 Home Respiratory Strategies in COPD Patients With Chronic Hypercapnic Respiratory Failure: A Systematic Review and Network Meta-analysis P616 Bronchoscopic Lung Volume Reduction With Endobronchial Zephyr Valves; A Systematic Review and Meta-analysis

ATS 2024 Conference Program • San Diego, CA